$0.76
4.43% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US44984F3029
Symbol
INVO

INVO Bioscience Inc Stock price

$0.76
-0.13 14.69% 1M
-0.41 34.91% 6M
-0.60 44.07% YTD
-0.56 42.59% 1Y
-76.45 99.02% 3Y
-189.33 99.60% 5Y
-37.65 98.03% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.04 4.43%
ISIN
US44984F3029
Symbol
INVO

Key metrics

Market capitalization $2.95m
Enterprise Value $14.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.58
P/S ratio (TTM) P/S ratio 0.51
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 390.03%
Revenue (TTM) Revenue $5.77m
EBIT (operating result TTM) EBIT $-5.24m
Free Cash Flow (TTM) Free Cash Flow $-3.97m
Cash position $940.00k
EPS (TTM) EPS $-2.54
Short interest 3.91%
Show more

Is INVO Bioscience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

INVO Bioscience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast INVO Bioscience Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast INVO Bioscience Inc:

Hold
100%

Financial data from INVO Bioscience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
5.77 5.77
389% 389%
100%
- Direct Costs 3.80 3.80
435% 435%
66%
1.97 1.97
328% 328%
34%
- Selling and Administrative Expenses 6.58 6.58
30% 30%
114%
- Research and Development Expense 0.01 0.01
98% 98%
0%
-4.62 -4.62
51% 51%
-80%
- Depreciation and Amortization 0.62 0.62
148% 148%
11%
EBIT (Operating Income) EBIT -5.24 -5.24
45% 45%
-91%
Net Profit -7.08 -7.08
30% 30%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about INVO Bioscience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

INVO Bioscience Inc Stock News

Neutral
GlobeNewsWire
4 months ago
SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial r...
Positive
InvestorPlace
5 months ago
Invo Bioscience (NASDAQ: INVO ) stock is rocketing higher on Wednesday alongside its earnings report for the fourth quarter of 2023. The healthcare services fertility company reported a net loss of $2 million during the quarter.
Neutral
GlobeNewsWire
5 months ago
SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial...
More INVO Bioscience Inc News

Company Profile

INVO BioScience, Inc. focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Medford, MA.

Head office United States
CEO Steven Shum
Employees 30
Founded 2007
Website www.invobioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today